Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,106 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

NCT02410551
View directory record Official record
Conditions
Myeloproliferative Diseases
Interventions
Pacritinib, Busulfan, Questionnaires, Phone Calls, Allogeneic Stem Cell Transplantation, Fludarabine
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated No phase listed Observational

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

NCT05109195
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Standard of Care (SOC)
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT05712356
View directory record Official record
Conditions
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions
certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Not yet recruiting Phase 2 Interventional

CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock

NCT07461961
View directory record Official record
Conditions
Cardiogenic Shock, Heart Failure, Inflammation
Interventions
Methylprednisone, Standard of Care (SOC)
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting No phase listed Observational

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

NCT04668872
View directory record Official record
Conditions
Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions
Y90 TARE, PET/CT, PET/MRI
Radiation · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 1 Interventional

CAN1012 in Pre-Malignant DCIS and LCIS

NCT07408856
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
Interventions
CAN1012
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed No phase listed Observational

Next Generation CT System

NCT06769594
View directory record Official record
Conditions
Computed Tomography
Interventions
Investigational CT Scan
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 4 Interventional

Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds

NCT03686904
View directory record Official record
Conditions
Wound Infection
Interventions
Benzalkonium Gel, standard of care topical gel, Debridement, benzalkonium irrigation, Saline Irrigation (SOC Irrigation)
Drug · Other · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271
View directory record Official record
Conditions
HIV Infections
Interventions
tipranavir, ritonavir, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Clearwater, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Intercostal CryoAnalgesia in Robotic Lung Resection

NCT05144828
View directory record Official record
Conditions
Pain, Postoperative, Lung Diseases
Interventions
Intercostal Nerve Cryoablation, Patient-controlled analgesia (PCA)
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

NCT06938347
View directory record Official record
Conditions
Right-To-Left Shunt
Interventions
Agitated Saline SoC, ASI-02
Drug
Lead sponsor
Agitated Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Not applicable Interventional

Enhanced Medical Rehabilitation for Spinal Cord Injury

NCT03952416
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Enhanced Medical Rehabilitation (EMR)
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Not applicable Interventional Results available

Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)

NCT03513068
View directory record Official record
Conditions
COPD
Interventions
Portable Oxygen Concentrator (POC)
Device
Lead sponsor
ResMed
Industry
Eligibility
40 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Denver, Colorado • Chicago, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
View directory record Official record
Conditions
Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)
Interventions
Allogeneic HSCT, Anti-thymocyte globulin (ATG), Cyclosporine (CSP), Mycophenolate mofetil (MMF), Total lymphoid irradiation (TLI), Methylprednisolone sodium succinate, Best standard care
Procedure · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
5
States / cities
Hayward, California • Los Angeles, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 15, 2026, 4:24 AM EDT
Recruiting Phase 3 Interventional

a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers

NCT07852338
View directory record Official record
Conditions
Diabetic Foot Ulcer, Amniotic Membrane Placental Allograft, Biologic
Interventions
All sentinel cohort participants will receive biologic plus SOC. who receive at least one treatment of the biologic plus SOC and complete the treatment period of 12 weeks., Standard wound care for diabetic foot ulcers, Participants in the randomized phase are assigned by randomization (2:1) to BIOxHEAL plus SOC or SOC alone. once weekly for up to 12 weeks or until complete ulcer closure
Biological · Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional Results available

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

NCT04914897
View directory record Official record
Conditions
Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions
THOR-707, Pembrolizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 1Phase 2 Interventional

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

NCT04335721
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Voxelotor
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 3 Interventional Results available

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

NCT05605093
View directory record Official record
Conditions
COVID-19
Interventions
Shionogi Protease Inhibitor (S-217622), placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
103
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 4:24 AM EDT
Not listed Phase 2 Interventional

Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities

NCT04667416
View directory record Official record
Conditions
Chronic Ulcer of Lower Extremity
Interventions
PalinGen Flow Amniotic Tissue Allograft
Biological
Lead sponsor
Amnio Technology, LLC
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Carmichael, California • Castro Valley, California • Fresno, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 15, 2026, 4:24 AM EDT
Terminated Phase 4 Interventional Results available

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

NCT03927911
View directory record Official record
Conditions
Postoperative Pain Management
Interventions
EXPAREL and Bupivacaine, Standard of Care
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
New Haven, Connecticut • Boca Raton, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 15, 2026, 4:24 AM EDT
Completed Not applicable Interventional

RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor

NCT05540626
View directory record Official record
Conditions
Essential Tremor
Interventions
Cala Trio
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 15, 2026, 4:24 AM EDT